Multi-institutional collaboration to characterize 5hmC in prostate cancer, both tumor biopsies and cfDNA.
This study used pull-down sequencing to measure 5-hydroxymethylcytosine (5hmC) levels in tissue biopsy specimens from patients with localized and metastatic castration-resistant (mCRPC) prostate cancer. For a subset of the cohort, the same technique was used to sequence cell-free DNA (cfDNA) isolated from patient plasma. To assess 5hmC levels in cfDNA from a larger number of specimens, plasma samples from another mCRPC cohort were also assayed with this method. The larger cohort of cfDNA samples was further anlayzed with a targeted sequencing gene panel.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001008462 | Illumina HiSeq 2500 NextSeq 550 | 596 |
Publications | Citations |
---|---|
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
Cancer Res 82: 2022 3888-3902 |
20 |
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer.
Nat Genet 56: 2024 1689-1700 |
1 |